Mesenchymal Stem Cells Manage Endogenous Tissue Regeneration

Meiliana, Anna; Dewi, Nurrani Mustika; Wijaya, Andi

doi:10.18585/inabj.v8i2.211

Cited by 10 publications

(7 citation statements)

References 142 publications

(171 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First clinical trials performed with stem cells to repair the non-haematopoietic tissues do with MSC. [32][33] MSCs have been subsequently found in many tissues, such as umbilical cord blood, adipose, brain, liver and lungs. [34][35][36][37][38][39][40] They seen as promising cells for the treatment of a large variety of disorders, including cardiovascular, neurodegenerative and autoimmune diseases.…”

Section: -31mentioning

confidence: 99%

Is Stem Cell a Curer or an Obstruction?

Darmayanti

Triana

Chouw

et al. 2017

Mol Cell Biomed Sci

Self Cite

View full text Add to dashboard Cite

Introduction: Each cell in human body is assigned with a specialized function to perform. Before a cell becomes specialized, it is a stem cell. Stem cell research and therapy is progressing dramatically these days. Stem cell therapy holds enormous treatment potential for many diseases which currently have no or limited therapeutic options. Unfortunately, this potential also comes with side-effects. In this review, the positive and negative effects of regulation of stem cells will be explained.Content: Stem cells are undifferentiated cells that have potential to develop into many different cell types in the body during early life and growth. The type of stem cells are embryonic stem cells, induced pluripotent stem cells, somatic stem cells, foetal stem cells and mesenchymal stem cells. Stem cell transplantation is one form of stem cell therapy, it comes with different sources, and those are autologous and allogenic transplantation stem cells. In an autologous transplant, a patient’s own blood-forming stem cells are collected, meanwhile in an allogeneic transplant, a person’s stem cells are replaced with new stem cells obtained from a donor or from donated umbilical cord blood.Summary: Its abilities to maintain undifferentiated phenotype, self-renewing and differentiate itself into specialized cells, give rise to stem cell as a new innovation for the treatment of various diseases. In the clinical setting, stem cells are being explored in various conditions, such as in tissue repair and regeneration and autoimmune diseases therapy. But along with its benefit, stem cell therapy also holds some harm. It is known that the treatment using stem cell for curing and rehabilitation has the risk in tumor formation.

show abstract

Section: -31mentioning

confidence: 99%

Is Stem Cell a Curer or an Obstruction?

Darmayanti

Triana

Chouw

et al. 2017

Mol Cell Biomed Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…In genetic disease like RP, revitalization of tissue will be more likely to happenthan regeneration. Mutated genes would likely initiate abnormal protein synthesis that leads to photoreceptor death but epigenetically MSC will influence the protein synthesis and support an optimal life of photoreceptor [23][24][25] .…”

Section: Discussionmentioning

confidence: 99%

Multifocalelectroretinography Result before and after Peribulbar Injection of Allogeneic Umbilical Cord – Mesenchymal Stem Cell Secretome for Late-Stage Retinitis Pigmentosa

2021

IJPHRD

View full text Add to dashboard Cite

Background: Retinitis Pigmentosa (RP) is a rare retinal genetic disease without available treatment to date. Previous studies show growth factor and regenerative ability of secretome from cultured allogeneic umbilical chord mesenchymal stem cells (UC-MSC). This studyaimed to report multifocal electroretinography of retinal photoreceptor responsefrom RP patients, before and after injection of secretome from allogeneicUC-MSC.Patients and Methods: Four subjects with severely damage retina (visual field defect of 25 %-50% in initial Humphrey perimetry examination) were recruited and givenperibulbar injection of secretome from allogeneic cultured UC-MSC. Visual acuity, visual field examination, multifocal electroretinogram of retinal photoreceptor examination were observed before and periodically after injection until six months period Results: Overall, we observed subtle changes in N1 and P1 amplitude and implicit time only in ring 1 at 1, 3 and 6 month post secretome injection. Conclusion:Peribulbar injection of allogeneic UC-MSC secretome had very miminal influence on photoreceptor activity in late-stage RP patients.

show abstract

“…MSCs are a promising candidate to treat COVID-19 because of the overreaction of the immune response. Hypothetically, MSCs act as the cell manager that re-activates the immune system to prevent the cytokine storm and promotes the endogenous repair [ 49 , 50 ].…”

Section: Msc Mechanism In Covid-19mentioning

confidence: 99%

Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19

Chouw

Milanda

Sartika³

et al. 2021

Regen. Eng. Transl. Med.

View full text Add to dashboard Cite

The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19. Lay Summary The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.

show abstract

Mesenchymal Stem Cells Manage Endogenous Tissue Regeneration

Cited by 10 publications

References 142 publications

Is Stem Cell a Curer or an Obstruction?

Is Stem Cell a Curer or an Obstruction?

Multifocalelectroretinography Result before and after Peribulbar Injection of Allogeneic Umbilical Cord – Mesenchymal Stem Cell Secretome for Late-Stage Retinitis Pigmentosa

Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19

Contact Info

Product

Resources

About